The Effect of Exenatide on Fasting Bile Acids

The Effect of Exenatide on Fasting Bile Acids in Newly Diagnosed Type 2 Diabetes Mellitus Patients, a Pilot Study

Newly diagnosed T2DM participants without hypoglycemic drugs intake were retrospective analyzed. Plasma total bile acids in fasting state (FTBAs) and other parameters were compared before and after exenatide treatment and correlation analysis between changes of FTBAs and glycemic parameters.

Newly diagnosed T2DM participants without hypoglycemic drugs intake were retrospective analyzed. Plasma total bile acids in fasting state (FTBAs) and other parameters were tested at baseline. Then exenatide were applied to the T2DM participants for 12 weeks. FTBAs and glycemic parameters were measured again after exenatide treatment, and correlation analysis between changes of FTBAs and glycemic parameters were conducted to investigate the role of BAs in the glycemic control effect of exenatide.

Inclusion Criteria:

• Newly diagnosed T2DM patients

Exclusion Criteria:

• History of hepatobiliary or pancreatic diseases
• History of anti-diabetic drugs intake
• Change of anti-dyslipidemia therapy regimen
• Estimated glomerular filtration rate less than 60 mL/min/1.73 m^2
• Pregnancy